NCT03922880 2025-05-15
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
Clinical Trials
6 trialsNCT02101580 2020-10-01
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Polaris Group
Phase 1 Completed
NCT01948843 2016-04-14
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
Polaris Group
Phase 1 Completed
NCT02101593 2016-03-04
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
Polaris Group
Phase 1 Completed
NCT01665183 2016-02-25
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Polaris Group
Phase 1 Completed
NCT00029900 2015-03-25
ADI-PEG in Patients With Metastatic Melanoma
FDA Office of Orphan Products Development
Phase 1 Completed